Cogent Biosciences Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone. Thank you for joining us today for the last day of JPMorgan's 41st Annual Healthcare Conference. I hope you are enjoying the conference so far. It's my pleasure to introduce you, Andy Robbins, CEO of Cogent Biosciences. My name is Tarun Soni, and I'm a health care while rent here the health -- Investment Banking Group at JPMorgan. Just housekeeping before we begin the presentation. If you have any questions, you can submit them via the portal or the traditional way of raising your hand and outstanding questions. So with that, Andrew, over to you. Thank you.
Great. Thanks, Tarun, and I appreciate the invite to be here at the JPMorgan conference to kick off the year. I'm excited to are sort of a forward-looking presentation about what does 2023 hold for Cogent Biosciences and potentially even after that. We're obviously very excited by the progress we've made, certainly with our lead drug, bezuclastinib over the past year as well as in building out what we think is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
